Clinical Trial

A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

Study acronym: RAD402
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-26; most recent amendment 2026-03-30.
Status change: Not Yet Recruiting → Recruiting 2026-03-11
Trial Details
NCT Number NCT07259213
Lead Sponsor Radiopharm Theranostics, Ltd
Conditions Castration-resistant Prostate Cancer
Enrollment 73 participants
Start Date 2026-03-05
Primary Completion 2028-11-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-01